Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer.

Kashiwa M, Fujimori M.

DOI: 10.1177/10600280261447399
Published: 2026-05-27
Container: Ann Pharmacother
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/10600280261447399,
  title = {Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer.},
  author = {Kashiwa M and  Fujimori M.},
  year = {2026},
  journal = {Ann Pharmacother},
  doi = {10.1177/10600280261447399},
  url = {https://doi.org/10.1177/10600280261447399}
}

RIS

TY  - JOUR
TI  - Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer.
AU  - Kashiwa M
AU  -  Fujimori M.
PY  - 2026
JO  - Ann Pharmacother
DO  - 10.1177/10600280261447399
UR  - https://doi.org/10.1177/10600280261447399
ER  -

APA

M, K., & M., F. (2026). Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer.. Ann Pharmacother. https://doi.org/10.1177/10600280261447399

Source records

europe-pmc · retrieved 2026-09-27T12:08:18.556Z